CML at a District General Hospital: Real-World Outcomes That Exceed International Benchmarks (SOHO 2026) - Sep 1, 2026 - Abstract #CML-111; "The imatinib contrast was striking...Every mutation-positive patient reached DMR, including those with T315I and compound kinase domain mutations requiring ponatinib or asciminib... A DGH can deliver CML outcomes that match and, in several respects, exceed international benchmarks without specialist center infrastructure. The TFR gap is addressable with the right pathway and patient support."
Clinical • Real-world • Real-world evidence • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR
|
|
Muhammad Mohsin MBBS FRCP,FRCPath; Emma Sedgwick BmedSci
|